[February 20, 2018]

Aranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) Drug Analysis 2018 - ResearchAndMarkets.com

The "Drug Analysis: Aranesp" drug pipelines has been added to ResearchAndMarkets.com's offering.

Aranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) is a recombinant human erythropoietin product administered by intravenous or subcutaneous injection, and is indicated for the treatment of anemia in chronic kidney disease and chemotherapy-induced anemia. The drug targets the erythropoietin receptor, initiating the same pathway as native erythropoietin, and triggering increased blood production in bone marrow.

Key Topics Covered:

Product Profiles

• Aranesp: Anemia in chronic kidney disease
• Aranesp: Chemotherapy-induced anemia

List of Figures

Figure 1: Aranesp for anemia in chronic kidney disease - SWOT nalysis

Figure 2: Drug assessment summary of Aranesp for anemia in chronic kidney disease

Figure 3: Drug assessment summary of Aranesp for anemia in chronic kidney disease

Figure 4: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24

Figure 5: Aranesp for chemotherapy-induced anemia - SWOT analysis

Figure 6: Drug assessment summary of Aranesp in chemotherapy-induced anemia

Figure 7: Drug assessment summary of Aranesp in chemotherapy-induced anemia

List of Tables

Table 1: Aranesp drug profile

Table 2: Aranesp pivotal trial data in anemia in chronic kidney disease

Table 3: Aranesp other late-phase trial data in anemia in chronic kidney disease

Table 4: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24

Table 5: Aranesp drug profile

Table 6: Aranesp pivotal trial data in chemotherapy-induced anemia

Table 7: Aranesp late-phase trial data in chemotherapy-induced anemia

Table 8: Aranesp ongoing late-phase clinical trial in chemotherapy-induced anemia

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/sgbf8x/aranesp?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180220006345/en/

[ Back To TMCnet.com's Homepage ]